Evidence map›Paper›PMID 40430490›Full record

ReviewPharmaceuticals (Basel, Switzerland)2025

Advances in Targeted Autophagy Modulation Strategies to Treat Cancer and Associated Treatment-Induced Cardiotoxicity.

Lauren A Ling, Asma Boukhalfa, Andrew H Kung, Vicky K Yang, Howard H Chen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lauren A LingMolecular Cardiology Research Institute, Tufts Medical Center, 800 Washington Street, #80, Boston, MA 02111, USA.ORCID 0000-0002-0012-6493
Asma BoukhalfaMolecular Cardiology Research Institute, Tufts Medical Center, 800 Washington Street, #80, Boston, MA 02111, USA.
Andrew H KungMolecular Cardiology Research Institute, Tufts Medical Center, 800 Washington Street, #80, Boston, MA 02111, USA.
Vicky K YangCummings School of Veterinary Medicine, Tufts University, 200 Westboro Rd., North Grafton, MA 01536, USA.ORCID 0000-0002-1281-4250
Howard H ChenMolecular Cardiology Research Institute, Tufts Medical Center, 800 Washington Street, #80, Boston, MA 02111, USA.ORCID 0000-0002-5145-0584

Funding

Credentialing a Cross-Species Platform to Investigate Cancer Therapy-Associated Cardiovascular ToxicityR01CA243542 · NCI · TUFTS MEDICAL CENTER · PI JAFFE, IRIS Z, LONDON, CHERYL A · 2019 to 2023
$3.1M
Monitoring Autophagy in the Heart and in Tumors Treated with Potentially Cardiotoxic ChemotherapyR01HL166810 · NHLBI · TUFTS MEDICAL CENTER · PI Howard H. Chen, David E Sosnovik · 2024 to 2026
$2.3M
Multiplexed Molecular Imaging of Cell Death PathwaysR00HL121152 · NHLBI · TUFTS MEDICAL CENTER · PI CHEN, HOWARD H. · 2017 to 2019
$747k
Naturally occurring canine myxomatous mitral valve disease as a large animal model for human non-syndromic mitral valve prolapseK01OD028205 · OD · TUFTS UNIVERSITY BOSTON · PI YANG, VICKY K. · 2019 to 2023
$691k
American Heart Association Career Development AwardNational Institute of Health K99/R00HL121152NCI NIH HHS R01 CA243542NHLBI NIH HHS R00 HL121152NHLBI NIH HHS R01 HL166810NIH HHS K01 OD028205
6 · The paper itself

Abstract

Autophagy, an evolutionarily conserved process, plays an important role in cellular homeostasis and human diseases. Cardiovascular dysfunction, which presents during cancer treatment or in cancer-free individuals years after treatment, is a growing clinical challenge. Millions of cancer survivors and patients face an unpredictable risk of developing cardiotoxicity. Cardiotoxicity due to cancer treatment, as well as cancer progression, has been linked to autophagy dysregulation. Modulating autophagy has been further proposed as a therapeutic treatment for both cancer and cardiovascular disorders. The safe and effective use of autophagy modulation as a cardioprotective strategy during cancer treatment especially requires careful consideration and experimentation to minimize the impact on cancer treatment. We focus here on recent advances in targeted autophagy modulation strategies that utilize interdisciplinary approaches in biomedical sciences and are potentially translatable to treat cardiotoxicity and improve cancer treatment outcomes. This review highlights non-small molecule autophagy modulators to enhance targeted therapy, nanomedicine for autophagy modulation and monitoring, and in vitro models and future experiments needed to bring novel autophagy discoveries from basic research to clinical translation.

Indexed as

apoptosisautophagycardio-oncologycardioprotectionnanotechnology

Identifiers

PMID40430490
PMCPMC12114528

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.